Ophthalmic Drugs as Part of Polypharmacy in Nursing Home Residents with Glaucoma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Glaucoma comprises age-related neurodegenerative diseases of retinal ganglion cells, the worldwide prevalence of which is increasing. Local pharmacotherapy is the primary treatment option, especially in the elderly. But this therapeutic approach may include risks for adverse drug effects and drug–drug interactions, of particular importance in frail nursing home resident populations.
The aim of the present study was to investigate anti-glaucoma pharmacotherapy in nursing home residents in the context of multi-morbidity and related systemic co-medication.
Data for 8,685 nursing home residents with 88,695 drug prescriptions were analysed according to diagnosis and local or systemic pharmacotherapy. Data were provided in anonymous form by a German public health insurance company.
The study cohort was characterized by a mean age of 83.6 ± 7.3 years (range: 65–106 years), 21 % of nursing home residents were at least 90 years old and 83.7 % were women. For each nursing home resident, an average of 6.0 ± 3.3 different drugs were registered. A diagnosis of glaucoma was recorded in 520 (6.0 %) nursing home residents; all subjects had co-existing medical conditions. Dementia was a frequent co-morbidity, diagnosed in 51.7 % of nursing home residents with glaucoma. Anti-glaucoma drugs contributed to 0.5 % of all prescriptions and were prescribed to 341 nursing home residents. The most frequently used anti-glaucoma ophthalmics were β-blockers (n = 219), followed by prostaglandin analogues (n = 101) and carbonic anhydrase inhibitors (n = 86). Local anti-glaucoma therapy was co-prescribed with a systemic pharmacotherapy in 338 nursing home residents. An ophthalmic agent was, on average, combined with 6.5 ± 3.2 prescriptions for systemic agents. Thus, 71.9 % of nursing home residents were prescribed ophthalmic β-blockers and a concomitant antihypertensive medication; local and systemic β-blockers were combined in 20.2 % of these patients. Co-treatment with cardiac glycosides or calcium antagonists was found in 13 % of nursing home residents prescribed ophthalmic parasympathomimetics, and in 14 % of those prescribed ophthalmic β-blockers, with the potential for drug–drug interactions to influence cardiac function.
Anti-glaucoma pharmacotherapy in nursing home residents is frequently prescribed in the context of polypharmacy. This may modify the efficacy and safety of local and systemic therapies. Therefore, individualized pharmacotherapy that integrates anti-glaucoma drug therapy into the overall treatment rationale in nursing home residents is necessary. However, to realize this concept, further clinical research in nursing home residents is warranted.
- Eichenbaum JW, Burton WB, Eichenbaum GM, et al. The prevalence of eye disease in nursing home and non-nursing home geriatric populations. Arch Gerontol Geriatr. 1999;28(3):191–204. CrossRef
- Whitmore WG. Eye disease in a geriatric nursing home population. Ophthalmology. 1989;96(3):393–8.
- Friedman DS, West SK, Munoz B, et al. Racial variations in causes of vision loss in nursing homes: the Salisbury eye evaluation in nursing home groups (SEEING) study. Arch Ophthalmol. 2004;122(7):1019–24. CrossRef
- Voytas JJ, Kowalski D, Wagner S, et al. Eye care in the skilled nursing facility: a pilot study of prevalence and treatment patterns of glaucoma. J Am Med Dir Assoc. 2004;5(3):156–60. CrossRef
- Brenner MH, Curbow B, Javitt JC, et al. Vision change and quality of life in the elderly: response to cataract surgery and treatment of other chronic ocular conditions. Arch Ophthalmol. 1993;111(5):680–5. CrossRef
- Legro MW. Quality of life and cataracts: a review of patient-centered studies of cataract surgery outcomes. Ophthalmic Surg. 1991;22(8):431–43.
- Long CA, Holden R, Mulkerrin E, et al. Opportunistic screening of visual acuity of elderly patients attending outpatient clinics. Age Ageing. 1991;20(6):392–5. CrossRef
- McMurdo ME, Baines PS. The detection of visual disability in the elderly. Health Bull (Edinb). 1988;46(6):327–9.
- Wang F, Javitt JC. Eye care for elderly Americans with diabetes mellitus: failure to meet current guidelines. Ophthalmology. 1996;103(11):1744–50.
- Wormald RP, Wright LA, Courtney P, et al. Visual problems in the elderly population and implications for services. BMJ. 1992;304(6836):1226–9. CrossRef
- Quigley HA. Glaucoma. Lancet. 2011;377(9774):1367–77. CrossRef
- Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31(5):986–1000. CrossRef
- Geers C, Gros G. Carbon dioxide transport and carbonic anhydrase in blood and muscle. Physiol Rev. 2000;80(2):681–715.
- Fraunfelder FT, Fraunfelder FW, Chambers WA, editors. Clinical ocular toxicology. Riverport: Saunders; 2008.
- Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol. 2002;240(6):430–5. CrossRef
- Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(Suppl. 1):S6–12. CrossRef
- Edeki TI, He H, Wood AJ. Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction. JAMA. 1995;274(20):1611–3. CrossRef
- Volotinen M, Korjamo T, Tolonen A, et al. Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes. Basic Clin Pharmacol Toxicol. 2010;106(4):302–9.
- Parsons C, Lapane K, Kerse N, et al. Prescribing for older people in nursing homes: a review of the key issues. Int J Older People Nurs. 2011;6(1):45–54. CrossRef
- WHO collaborating centre for drug statistics methodology. Anatomical therapeutic chemical (ATC) classification system. 2012. http://www.whocc.no/atc_ddd_index/. Accessed 2012 Nov 9.
- World Health Organization. International statistical classification of diseases and related health problems. 10th ed. 2010. http://www.who.int/classifications/icd/en/. Accessed 2012 Nov 9.
- European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd ed. 2008. http://www.eugs.org/eng/EGS_guidelines.asp. Accessed 2012 Nov 9.
- Azermai M, Elseviers M, Petrovic M, et al. Assessment of antipsychotic prescribing in Belgian nursing homes. Int Psychogeriatr. 2011;23(8):1240–8. CrossRef
- Nishtala PS, McLachlan AJ, Bell JS, et al. Determinants of antipsychotic medication use among older people living in aged care homes in Australia. Int J Geriatr Psychiatry. 2010;25(5):449–57. CrossRef
- Parsons C, Briesacher BA, Givens JL, et al. Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia. J Am Geriatr Soc. 2011;59(7):1253–9. CrossRef
- Tjia J, Rothman MR, Kiely DK, et al. Daily medication use in nursing home residents with advanced dementia. J Am Geriatr Soc. 2010;58(5):880–8. CrossRef
- Heijl A. Perimetry, tonometry and epidemiology: the fate of glaucoma management. Acta Ophthalmol. 2011;89(4):309–15. CrossRef
- Phan TM, Nguyen KP, Giacomini JC, et al. Ophthalmic beta-blockers: determination of plasma and aqueous humor levels by a radioreceptor assay following multiple doses. J Ocul Pharmacol. 1991;7(3):243–52.
- Henness S, Swainston HT, Keating GM. Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension. Drugs Aging. 2007;24(6):509–28. CrossRef
- Kawase K, Yamamoto T, Muramatsu T, et al. Long-acting carteolol hydrochloride 2% ophthalmic solution phase IV study: investigation of the effectiveness, safety and plasma concentration (in Japanese). Nihon Ganka Gakkai Zasshi. 2010;114(11):976–82.
- Nieminen T, Lehtimaki T, Maenpaa J, et al. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest. 2007;67(2):237–45. CrossRef
- Nieminen T, Uusitalo H, Turjanmaa V, et al. Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol. 2005;61(5–6):369–74. CrossRef
- Raber S, Courtney R, Maeda-Chubachi T, et al. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study. Ophthalmology. 2011;118(10):2022–7. CrossRef
- Costa VP, Harris A, Stefansson E, et al. The effects of antiglaucoma and systemic medications on ocular blood flow. Prog Retin Eye Res. 2003;22(6):769–805. CrossRef
- Mant J, Al-Mohammad A, Swain S, et al. Management of chronic heart failure in adults: synopsis of the National Institute for Health and Clinical Excellence guideline. Ann Intern Med. 2011;155(4):252–9. CrossRef
- Lee AJ, Wang JJ, Kifley A, et al. Open-angle glaucoma and cardiovascular mortality: the Blue Mountains Eye Study. Ophthalmology. 2006;113(7):1069–76. CrossRef
- Volotinen M, Hakkola J, Pelkonen O, et al. Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011;108(5):297–303. CrossRef
- Novack GD, O’Donnell MJ, Molloy DW. New glaucoma medications in the geriatric population: efficacy and safety. J Am Geriatr Soc. 2002;50(5):956–62. CrossRef
- Beers MH, Ouslander JG, Fingold SF, et al. Inappropriate medication prescribing in skilled-nursing facilities. Ann Intern Med. 1992;117(8):684–9. CrossRef
- Doshi JA, Shaffer T, Briesacher BA. National estimates of medication use in nursing homes: findings from the 1997 medicare current beneficiary survey and the 1996 medical expenditure survey. J Am Geriatr Soc. 2005;53(3):438–43. CrossRef
- Batchelor ED, O’Day DM, Shand DG, et al. Interaction of topical and oral timolol in glaucoma. Ophthalmology. 1979;86(1):60–5.
- Blondeau P, Cote M, Tetrault L. Effect of timolol eye drops in subjects receiving systemic propranolol therapy. Can J Ophthalmol. 1983;18(1):18–21.
- Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology. 2000;107(6):1171–7. CrossRef
- Goldberg I, Adena MA. Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: a quality use of medicine issue in Australian practice. Clin Exp Ophthalmol. 2007;35(8):700–5. CrossRef
- Gottfredsdottir MS, Allingham RR, Shields MB. Physicians’ guide to interactions between glaucoma and systemic medications. J Glaucoma. 1997;6(6):377–83. CrossRef
- Ophthalmic Drugs as Part of Polypharmacy in Nursing Home Residents with Glaucoma
Drugs & Aging
Volume 30, Issue 1 , pp 31-38
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing AG
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Institute of Clinical Pharmacology and Toxicology, Charité, Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
- 2. Institute of Medical Sociology, Charité, Universitätsmedizin Berlin, Berlin, Germany